Further, in this translational study, we confirmed that monitoring of HER2ECD values represent a clinically relevant complementary assessment in order to compensate inter-laboratory and inter-observer discrepancies in HER2 overexpression, particularly when detected in small biopsies of metastatic disease or in very old tissue specimens. The gene discussed is ERBB2; the disease is metastatic neoplasm.